health
Povorcitinib improved facial repigmentation in two phase 3 vitiligo trials
In two 52-week placebo-controlled phase 3 trials, once-daily povorcitinib improved facial repigmentation in adults with moderate-to-severe nonsegmental vitiligo. The primary response threshold was reached by 18.9% of participants taking the drug in each trial.